Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST
Danielle Roman, PharmD, BCOP, and Rachelle Whiteside, PharmD
From West Penn Allegheny Oncology Network, Pittsburgh, Pennsylvania
The authors have no conflicts of interest to disclose.
Correspondence to: Danielle Roman, PharmD, BCOP, West Penn Allegheny Oncology Network, 4815 Liberty Avenue, Suite 340, Pittsburgh, PA 15317. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2013;4:118–122 |
DOI: 10.6004/jadpro.2013.4.2.7 |
© 2013 Harborside Press®
In late 2012, regorafenib (Stivarga), a novel oral multikinase inhibitor, was approved by the FDA for certain previously treated patients with metastatic colorectal cancer. Even more recently, regorafenib received another approval for use in select patients with refractory gastrointestinal stromal tumor. Read about key clinical trials, mechanism of action, adverse effects, and dosing and administration guidelines associated with this generally well-tolerated agent.
For access to the full length article, please sign in